ホーム
マーケット
チャート&アイデア
Algo
ニュース
Store
ブローカー
ダウンロード
経済指標カレンダー
取引シグナル
Webターミナル
「
/
」を入力して検索:@user、$symbol
検索
ログイン
アカウントを作成
日本語
English
Русский
中文
Español
Português
Deutsch
한국어
Français
Italiano
Türkçe
GPCR
#725
Structure Therapeutics Inc. American Depositary Shares
62.980
0
-0.54%
セクター:
ベース:
利益通貨:
日中レンジ
1年のレンジ
1日の変化
-0.54%
月次変化
-29.15%
6か月変化
+135.53%
1年の変化
+135.53%
以前の終値
63.325
0
Open
62.950
0
Bid
Ask
Low
62.950
0
High
62.980
0
ボリューム
46
マーケット
株
ヘルスケア
GPCR
Open full chart
Financials
Overview
明細書
Statistics
Dividends
Quarterly
Annual
Value
2023
2024
2025
TTM
Key stats
Total common shares outstanding
139.79 M
172.03 M
212.53 M
—
Valuation ratios
Enterprise value
5.52 B
4.5 B
13.98 B
25.25 B
Price to earnings ratio
-49.86
-34.77
-86.94
-149.77
Price to sales ratio
—
—
—
—
Price to cash flow ratio
55.99
36.72
55.59
122.51
Price to book ratio
9.83
4.95
8.15
11.44
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
-0.19
-0.14
0.09
-0.23
Return on equity %
-0.2
-0.14
0.09
-0.24
Return on invested capital %
-2 016.2
-2 707.26
1 067.7
-2 433.5
Gross margin %
—
—
—
—
Operating margin %
—
—
—
—
EBITDA margin %
—
—
—
—
Net margin %
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
19.14
24.74
24.81
82.73
Inventory turnover
—
—
—
—
Asset turnover
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
-0.72
-0.74
1.25
-0.55
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
4.24
5.59
8.14
22.18
Net current asset value per share
4.3
5.64
8.84
23.11
Tangible book value per share
4.11
5.48
8.54
22.25
Working capital per share
4.07
5.42
8.49
21.99
Book value per share
4.11
5.48
8.54
22.25
ニュース
Structure Therapeutics株、肥満治療薬データで上昇の可能性とCantor
Structure Therapeutics shares could rise on obesity drug data, Cantor says
Citizens、パイプライン拡大を受けStructure Therapeuticsの目標株価を引き下げ
Citizens cuts Structure Therapeutics stock price target on pipeline expansion
Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead?
Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026
Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin
Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough? (GPCR)
Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition?
How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report
Eli Lilly's 2025 Surge Sets the Stage for Another Big Year in 2026
Hims & Hers Health Stops Offering Knockoff Wegovy Pill Amid FDA Crackdown